Upamostat

CAS No. 590368-25-5

Upamostat( WX-671 )

Catalog No. M24583 CAS No. 590368-25-5

Upamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 222 In Stock
10MG 357 In Stock
25MG 597 In Stock
50MG 851 In Stock
100MG 1152 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Upamostat
  • Note
    Research use only, not for human use.
  • Brief Description
    Upamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor.
  • Description
    Upamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor.(In Vitro):Upamostat is the urokinase plasminogen activator (uPA) inhibitor. Upamostat is the oral pro-drug of the active metabolite WX-UK1, a novel uPA inhibitor. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, which plays a major role in tumor invasion and metastasis. Upamostat is the orally available amidoxime- (i.e. hydroxyamidine-) prodrug of the pharmacologically active form, WX-UK1.(In Vivo):The validated method is used to evaluate the pharmacokinetics of Upamostat (Mesupron) in rats. The mean plasma concentrations of Upamostat after a single intravenous injection of 2 mg/kg in five rats are measured. The substance decays in a mono-phasic pattern with a terminal half-life of 0.5 h; its volume of distribution is 2.0 L/kg, and clearance is about 2.7 L/h/kg.
  • In Vitro
    Upamostat is the urokinase plasminogen activator (uPA) inhibitor. Upamostat is the oral pro-drug of the active metabolite WX-UK1, a novel uPA inhibitor. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, which plays a major role in tumor invasion and metastasis. Upamostat is the orally available amidoxime- (i.e. hydroxyamidine-) prodrug of the pharmacologically active form, WX-UK1.
  • In Vivo
    The validated method is used to evaluate the pharmacokinetics of Upamostat (Mesupron) in rats. The mean plasma concentrations of Upamostat after a single intravenous injection of 2 mg/kg in five rats are measured. The substance decays in a mono-phasic pattern with a terminal half-life of 0.5 h; its volume of distribution is 2.0 L/kg, and clearance is about 2.7 L/h/kg.
  • Synonyms
    WX-671
  • Pathway
    Proteasome/Ubiquitin
  • Target
    Serine Protease
  • Recptor
    Serine protease
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    590368-25-5
  • Formula Weight
    629.81
  • Molecular Formula
    C32H47N5O6S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (396.95 mM)
  • SMILES
    CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC2=CC(=CC=C2)/C(=N/O)/N)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Heinemann V, et al. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
molnova catalog
related products
  • Isochlorogenic acid ...

    Isochlorogenic acid C has antioxidant activity.

  • Upamostat

    Upamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor.

  • SLK/STK10-IN-1

    SLK/STK10-IN-1 is a selective and potent inhibitor of SLK and STK10 with potential antitumor activity.